Urine markers for detection and surveillance of bladder cancer
Urine markers for detection and surveillance of bladder cancer
复制标题
DOI：
10.1016/j.urolonc.2013.06.001
复制
发表时间：
2014-04-01
影响因子：
2.7
通讯作者：
Shariat, Shahrokh F.
中科院分区：
文献类型：
--
作者：
Xylinas, Evanguelos;Kluth, Luis A.;Shariat, Shahrokh F.
目的：膀胱癌的检测和监测包括膀胱镜检查和细胞学检查。尿细胞学检查因其对低级别肿瘤的敏感性低而受到限制。尿液标记物已被广泛研究，以帮助改善膀胱癌的诊断，目的是补充甚至取代膀胱镜检查。然而，到目前为止，没有标志物已达到广泛使用，由于临床benefit.Material和方法的证据不足：Pubmed/Medline搜索进行识别原始文章，评论文章，和社论关于尿为基础的生物标志物的筛查，早期检测和监测膀胱尿路上皮癌。这些活动仅限于英语，时间范围为2000年至2013年。关键词包括尿路上皮癌，膀胱癌，移行细胞癌，生物标志物，标志物，尿液，诊断，复发，progression.Results：虽然几个尿液标志物已显示出较高的敏感性与细胞学相比，它仍然不足以取代膀胱镜检查。此外，大多数标记物的特异性低于细胞学。在这篇综述中，我们的目的是总结目前的知识，市售和有前途的研究尿液标记物的检测和监测膀胱cancer.Conclusions：精心设计的协议和前瞻性，对照试验需要提供的基础，以确定是否整合到临床决策的生物标志物将是有价值的膀胱癌检测和筛查在未来。(C)2014爱思唯尔公司All rights reserved.
Objectives: Bladder cancer detection and surveillance includes cystoscopy and cytology. Urinary cytology is limited by its low sensitivity for low-grade tumors. Urine markers have been extensively studied to help improve the diagnosis of bladder cancer with the goal of complementing or even replacing cystoscopy. However, to date, no marker has reached widespread use owing to insufficient evidence for clinical benefit.Material and methods: Pubmed/Medline search was conducted to identify original articles, review articles, and editorials regarding urine-based biomarkers for screening, early detection, and surveillance of urothelial carcinoma of the bladder. Searches were limited to the English language, with a time frame of 2000 to 2013. Keywords included urothelial carcinoma, bladder cancer, transitional cell carcinoma, biomarker, marker, urine, diagnosis, recurrence, and progression.Results: Although several urinary markers have shown higher sensitivity compared with cytology, it remains insufficient to replace cystoscopy. Moreover, most markers suffer from lower specificity than cytology. In this review, we aimed to summarize the current knowledge on commercially available and promising investigational urine markers for the detection and surveillance of bladder cancer.Conclusions: Well-designed protocols and prospective, controlled trials are needed to provide the basis to determine whether integration of biomarkers into clinical decision making will be of value for bladder cancer detection and screening in the future. (C) 2014 Elsevier Inc. All rights reserved.